ASX Growth Stocks With High Insider Ownership December 2025

As the Australian market approaches the end of 2025, it appears to be in a reflective mood with a slight dip as investors engage in profit-taking before the holiday break, despite Wall Street’s indices nearing record highs. In this environment, growth companies with high insider ownership can present appealing opportunities due to their potential for alignment between management and shareholder interests.

Click here to see the full list of 111 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let’s uncover some gems from our specialized screener.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$625.50 million.

Operations: The company generates revenue of A$95.02 million from its biopharmaceutical sector, focusing on treatments for various disorders across multiple regions.

Insider Ownership: 10.3%

Clinuvel Pharmaceuticals is poised for robust growth, with earnings forecast to rise 23.9% annually, outpacing the Australian market. Despite a projected low Return on Equity of 18.8%, Clinuvel’s revenue is expected to grow at 22% per year, surpassing market averages. The company trades significantly below its estimated fair value and maintains a disciplined approach to acquisitions, focusing on North American opportunities that align with its risk-adjusted return criteria while ensuring operational resilience and strategic capital deployment.

• Get an in-depth perspective on Clinuvel Pharmaceuticals’ performance by reading our analyst estimates report here.

• According our valuation report, there’s an indication that Clinuvel Pharmaceuticals’ share price might be on the cheaper side.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.10 billion.

Operations: The company generates revenue of A$1.16 billion from its residential aged care, home care, and retirement living services in Australia.